Balchem Co. (BCPC) Expected to Post Quarterly Sales of $164.00 Million

Wall Street brokerages expect Balchem Co. (NASDAQ:BCPC) to report $164.00 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Balchem’s earnings, with the lowest sales estimate coming in at $157.00 million and the highest estimate coming in at $171.00 million. Balchem posted sales of $161.41 million during the same quarter last year, which suggests a positive year over year growth rate of 1.6%. The business is expected to report its next quarterly earnings report on Friday, May 3rd.

On average, analysts expect that Balchem will report full-year sales of $711.15 million for the current year, with estimates ranging from $660.30 million to $762.00 million. For the next fiscal year, analysts expect that the firm will report sales of $801.25 million, with estimates ranging from $688.50 million to $914.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Balchem.

Balchem (NASDAQ:BCPC) last issued its quarterly earnings data on Thursday, February 28th. The basic materials company reported $0.77 EPS for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.11. Balchem had a return on equity of 14.59% and a net margin of 12.21%. The firm had revenue of $163.50 million during the quarter, compared to the consensus estimate of $161.42 million. Balchem’s revenue was up 2.6% on a year-over-year basis.

BCPC has been the subject of several recent analyst reports. HC Wainwright set a $101.00 price target on Balchem and gave the stock a “buy” rating in a research note on Monday, December 10th. BidaskClub raised Balchem from a “sell” rating to a “hold” rating in a research note on Wednesday, February 20th. Zacks Investment Research cut Balchem from a “buy” rating to a “hold” rating in a research note on Monday, February 18th. Finally, Seaport Global Securities initiated coverage on Balchem in a research note on Thursday, February 21st. They issued a “neutral” rating for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. Balchem has an average rating of “Hold” and an average price target of $105.50.

Shares of NASDAQ:BCPC traded up $0.09 on Friday, hitting $94.65. The company’s stock had a trading volume of 88,683 shares, compared to its average volume of 159,705. Balchem has a 12 month low of $73.16 and a 12 month high of $117.79. The stock has a market cap of $3.03 billion, a price-to-earnings ratio of 31.45 and a beta of 1.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.94 and a current ratio of 2.76.

Several institutional investors have recently made changes to their positions in BCPC. Norges Bank acquired a new stake in shares of Balchem in the fourth quarter valued at $33,642,000. BlackRock Inc. lifted its stake in Balchem by 5.6% in the 3rd quarter. BlackRock Inc. now owns 4,647,513 shares of the basic materials company’s stock worth $520,940,000 after acquiring an additional 245,174 shares in the last quarter. Vanguard Group Inc lifted its stake in Balchem by 2.6% in the 3rd quarter. Vanguard Group Inc now owns 3,252,944 shares of the basic materials company’s stock worth $364,622,000 after acquiring an additional 81,119 shares in the last quarter. Vanguard Group Inc. lifted its stake in Balchem by 2.6% in the 3rd quarter. Vanguard Group Inc. now owns 3,252,944 shares of the basic materials company’s stock worth $364,622,000 after acquiring an additional 81,119 shares in the last quarter. Finally, Macquarie Group Ltd. lifted its stake in Balchem by 16.8% in the 3rd quarter. Macquarie Group Ltd. now owns 385,069 shares of the basic materials company’s stock worth $43,162,000 after acquiring an additional 55,333 shares in the last quarter. Institutional investors and hedge funds own 87.80% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.

Read More: Capital gains and your 401(k) or IRA

Get a free copy of the Zacks research report on Balchem (BCPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.